Adipokines and inflammation markers and risk of differentiated thyroid carcinoma: The EPIC study

Other than the influence of ionizing radiation and benign thyroid disease, little is known about the risk factors for differentiated thyroid cancer (TC) which is an increasing common cancer worldwide. Consistent evidence shows that body mass is positively associated with TC risk. As excess weight is a state of chronic inflammation, we investigated the relationship between concentrations of leptin, adiponectin, C‐reactive protein, interleukin (IL)‐6, IL‐10 and tumor necrosis factor (TNF)‐α and the risk of TC. A case‐control study was nested within the European Prospective Investigation into Cancer and Nutrition (EPIC) study and included 475 first primary incident TC cases (399 women and 76 men) and 1,016 matched cancer‐free cohort participants. Biomarkers were measured in serum samples using validated and highly sensitive commercially available immunoassays. Odds ratios (ORs) of TC by levels of each biomarker were estimated using conditional logistic regression models, adjusting for BMI and alcohol consumption. Adiponectin was inversely associated with TC risk among women (ORT3vs.T1 = 0.69, 95% CI: 0.49–0.98, Ptrend = 0.04) but not among men (ORT3vs.T1 = 1.36, 95% CI: 0.67–2.76, Ptrend = 0.37). Increasing levels of IL‐10 were positively associated with TC risk in both genders and significantly so in women (ORT3vs.T1 = 1.59, 95% CI: 1.13–2.25, Ptrend = 0.01) but not in men (ORT3vs.T1 = 1.78, 95% CI: 0.80–3.98, Ptrend = 0.17). Leptin, CRP, IL‐6 and TNF‐α were not associated with TC risk in either gender. These results indicate a positive association of TC risk with IL‐10 and a negative association with adiponectin that is probably restricted to women. Inflammation may play a role in TC in combination with or independently of excess weight.

[1]  G. Kismali,et al.  Evaluation of Proinflammatory Cytokine and Neopterin Levels in Women with Papillary Thyroid Carcinoma , 2016, The International journal of biological markers.

[2]  K. Straif,et al.  Body Fatness and Cancer--Viewpoint of the IARC Working Group. , 2016, The New England journal of medicine.

[3]  Martyn Plummer,et al.  Worldwide Thyroid-Cancer Epidemic? The Increasing Impact of Overdiagnosis. , 2016, The New England journal of medicine.

[4]  P. Scherer,et al.  Adiponectin, Leptin, and Fatty Acids in the Maintenance of Metabolic Homeostasis through Adipose Tissue Crosstalk. , 2016, Cell metabolism.

[5]  Li-Ling Wu,et al.  Circulating adiponectin levels in various malignancies: an updated meta-analysis of 107 studies , 2016, Oncotarget.

[6]  T. Trivedi,et al.  Significance of Interleukin-6 in Papillary Thyroid Carcinoma , 2016, Journal of thyroid research.

[7]  Elizabeth E Ward,et al.  Anthropometric Factors and Thyroid Cancer Risk by Histological Subtype: Pooled Analysis of 22 Prospective Studies. , 2016, Thyroid : official journal of the American Thyroid Association.

[8]  G. H. Patel,et al.  Significance of TNF-α and the Adhesion Molecules: L-Selectin and VCAM-1 in Papillary Thyroid Carcinoma , 2016, Journal of thyroid research.

[9]  E. Mingomataj,et al.  Regulator Versus Effector Paradigm: Interleukin-10 as Indicator of the Switching Response , 2016, Clinical Reviews in Allergy & Immunology.

[10]  M. Leitzmann,et al.  Adiposity and risk of thyroid cancer: a systematic review and meta‐analysis , 2015, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[11]  N. Serdarevic,et al.  IL-4, IL-10 and high sensitivity-CRP as potential serum biomarkers of persistent/recurrent disease in papillary thyroid carcinoma with/without Hashimoto's thyroiditis , 2015, Scandinavian journal of clinical and laboratory investigation.

[12]  Z. Jovanovic,et al.  Cytokine production in patients with papillary thyroid cancer and associated autoimmune Hashimoto thyroiditis , 2015, Cancer Immunology, Immunotherapy.

[13]  I. Gram,et al.  Inflammatory Markers and Risk of Epithelial Ovarian Cancer by Tumor Subtypes: The EPIC Cohort , 2015, Cancer Epidemiology, Biomarkers & Prevention.

[14]  J. Araújo,et al.  The Role of the Mediators of Inflammation in Cancer Development , 2015, Pathology & Oncology Research.

[15]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[16]  S. Gandini,et al.  Circulating adiponectin and breast cancer risk: a systematic review and meta-analysis. , 2014, International journal of epidemiology.

[17]  U. Nöthlings,et al.  Inflammatory and metabolic biomarkers and risk of liver and biliary tract cancer , 2014, Hepatology.

[18]  M. Plummer,et al.  Thyroid-stimulating hormone, thyroglobulin, and thyroid hormones and risk of differentiated thyroid carcinoma: the EPIC study. , 2014, Journal of the National Cancer Institute.

[19]  T. Abdel-Aziz,et al.  Study of Serum Leptin in Well-differentiated Thyroid Carcinoma: Correlation with Patient and Tumor Characteristics , 2014, World Journal of Surgery.

[20]  T. Sergentanis,et al.  Interleukins as markers of inflammation in malignant and benign thyroid disease , 2014, Inflammation Research.

[21]  F. Clavel-Chapelon,et al.  C-reactive protein and postmenopausal breast cancer risk: results from the E3N cohort study , 2014, Cancer Causes & Control.

[22]  Y. Altuntas,et al.  Interleukin-10-1082 gene polymorphism is associated with papillary thyroid cancer , 2014, Molecular Biology Reports.

[23]  Zhibin Chen,et al.  Autoimmunity as a Double Agent in Tumor Killing and Cancer Promotion , 2014, Front. Immunol..

[24]  Vandana Saini,et al.  Role of leptin and adiponectin in insulin resistance. , 2013, Clinica chimica acta; international journal of clinical chemistry.

[25]  Chien-Liang Liu,et al.  Expression and Biologic Significance of Adiponectin Receptors in Papillary Thyroid Carcinoma , 2012, Cell Biochemistry and Biophysics.

[26]  C. Mantzoros,et al.  The role of adiponectin in cancer: a review of current evidence. , 2012, Endocrine reviews.

[27]  R. Melillo,et al.  Inflammation in thyroid oncogenesis. , 2012, American journal of cancer research.

[28]  J. Chang-Claude,et al.  Tumor necrosis factor (TNF)‐α, soluble TNF receptors and endometrial cancer risk: The EPIC study , 2011, International journal of cancer.

[29]  C. Mantzoros,et al.  Circulating adiponectin is inversely associated with risk of thyroid cancer: in vivo and in vitro studies. , 2011, The Journal of clinical endocrinology and metabolism.

[30]  L. L. Cunha,et al.  Interleukin-10 but not interleukin-18 may be associated with the immune response against well-differentiated thyroid cancer , 2011, Clinics.

[31]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[32]  Hong-Kyu Kim,et al.  High-Sensitivity C-Reactive Protein and Cancer , 2011, Journal of epidemiology.

[33]  F. Clavel-Chapelon,et al.  Obesity, inflammatory markers, and endometrial cancer risk: a prospective case–control study , 2010, Endocrine-related cancer.

[34]  G. Hallmans,et al.  Temporal reliability of cytokines and growth factors in EDTA plasma , 2010, BMC Research Notes.

[35]  E. Ron,et al.  Exposing the thyroid to radiation: a review of its current extent, risks, and implications. , 2010, Endocrine reviews.

[36]  F. Clavel-Chapelon,et al.  Circulating C-reactive protein concentrations and risks of colon and rectal cancer: a nested case-control study within the European Prospective Investigation into Cancer and Nutrition. , 2010, American journal of epidemiology.

[37]  R. Orlando,et al.  Cytokines, thyroid diseases and thyroid cancer. , 2010, Cytokine.

[38]  M. Castellone,et al.  Thyroid cancer and inflammation , 2010, Molecular and Cellular Endocrinology.

[39]  R. Ferris,et al.  Multiplex analysis of cytokines as biomarkers that differentiate benign and malignant thyroid diseases , 2008, Proteomics. Clinical applications.

[40]  Nahum Sonenberg,et al.  The Effects of Adiponectin and Metformin on Prostate and Colon Neoplasia Involve Activation of AMP-Activated Protein Kinase , 2008, Cancer Prevention Research.

[41]  M. Karadeniz,et al.  Interleukin-10 gene polymorphism in patients with papillary thyroid cancer in Turkish population , 2008, Journal of endocrinological investigation.

[42]  C. Dive,et al.  Obesity and cancer: Pathophysiological and biological mechanisms , 2008, Archives of physiology and biochemistry.

[43]  W. Willett,et al.  Plasma adiponectin concentrations and risk of incident breast cancer. , 2006, The Journal of clinical endocrinology and metabolism.

[44]  C. Friedenreich,et al.  Plasma adiponectin levels and endometrial cancer risk in pre- and postmenopausal women. , 2007, The Journal of clinical endocrinology and metabolism.

[45]  Herbert Tilg,et al.  Adipocytokines: mediators linking adipose tissue, inflammation and immunity , 2006, Nature Reviews Immunology.

[46]  L. Ricci-Vitiani,et al.  Autocrine production of interleukin-4 and interleukin-10 is required for survival and growth of thyroid cancer cells. , 2006, Cancer research.

[47]  S. Kihara,et al.  Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[48]  C. la Vecchia,et al.  A pooled analysis of case–control studies of thyroid cancer. IV. Benign thyroid diseases , 1999, Cancer Causes & Control.

[49]  K. Wellen,et al.  Obesity-induced inflammatory changes in adipose tissue. , 2003, The Journal of clinical investigation.

[50]  R. Henry,et al.  Adiponectin: more than just another fat cell hormone? , 2003, Diabetes care.

[51]  S. Katayose,et al.  Decreased plasma adiponectin concentrations in women with low-grade C-reactive protein elevation. , 2003, European journal of endocrinology.

[52]  N E Day,et al.  European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection , 2002, Public Health Nutrition.

[53]  S. Uchida,et al.  Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase , 2002, Nature Medicine.

[54]  G M Besser,et al.  Serum cytokines in thyrotoxicosis. , 1999, The Journal of clinical endocrinology and metabolism.